Evidence map›Paper›PMID 36279695›Full record

Observational studyJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2022

NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.

Franziska Hielscher, Tina Schmidt, Verena Klemis, Alexander Wilhelm, Stefanie Marx, Amina Abu-Omar, Laura Ziegler, Candida Guckelmus, Rebecca Urschel, Urban Sester and 2 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Franziska HielscherDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Tina SchmidtDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Verena KlemisDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Alexander WilhelmInstitute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Germany.
Stefanie MarxDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Amina Abu-OmarDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Laura ZieglerDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Candida GuckelmusDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Rebecca UrschelDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany.
Urban SesterDepartment of Nephrology, SHG-Klinikum Völklingen, Germany.
Marek WideraInstitute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Germany.
Martina SesterDepartment of Transplant and Infection Immunology, Institutes of Infection Medicine, Saarland University, Building 47, Kirrberger Straße D, Homburg 66421, Germany. Electronic address: martina.sester@uks.eu.
Saarland University · DEGoethe University Frankfurt · DEKlinikum Esslingen · DEUniversitätsklinikum des Saarlandes · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe NVX-CoV2373-vaccine has recently been licensed, although knowledge on vaccine-induced humoral and cellular immunity towards the parental strain and variants of concern (VOCs) in comparison to mRNA-regimens is limited.

methodsIn this observational study, 66 individuals were recruited to compare immunogenicity and reactogenicity of NVX-CoV2373 with BNT162b2 or mRNA-1273. Vaccine-induced antibodies were analyzed using ELISA and neutralization assays, specific CD4 and CD8 T-cells were characterized based on intracellular cytokine staining using flow-cytometry after antigen-specific stimulation with parental spike or VOCs.

resultsTwo doses of NVX-CoV2373 strongly induced anti-spike IgG, although IgG-levels were lower than after vaccination with BNT162b2 or mRNA-1273 (p = 0.006). Regardless of the vaccine and despite different IgG-levels, neutralizing activity towards VOCs was highest for Delta, followed by BA.2 and BA.1. The protein-based vaccine failed to induce any spike-specific CD8 T-cells which were detectable in 3/22 (14%) individuals only. In contrast, spike-specific CD4 T-cells were induced in 18/22 (82%) individuals, although their levels were lower (p<0.001), had lower CTLA-4 expression (p<0.0001) and comprised less multifunctional cells co-expressing IFNγ, TNFα and IL-2 (p = 0.0007). Unlike neutralizing antibodies, NVX-CoV2373-induced CD4 T-cells equally recognized all tested VOCs from Alpha to Omicron. In individuals with a history of infection, one dose of NVX-CoV2373 had similar immunogenicity as two doses in non-infected individuals. The vaccine was overall well tolerated.

conclusionNVX-CoV2373 strongly induced spike-specific antibodies and CD4 T-cells, albeit at lower levels as mRNA-regimens. Cross-reactivity of CD4 T-cells towards the parental strain and all tested VOCs may hold promise to protect from severe disease.

Indexed as

COVID-19COVID-19 Vaccines2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineHumansImmunity, HumoralImmunoglobulin GSARS-CoV-2Spike Glycoprotein, CoronavirusVaccination2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GNVX-CoV2373 adjuvated lipid nanoparticleSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2AntibodiesCoronavirusCOVID-19NeutralizationSARS-CoV-2T-cellsVaccinationVariant of concern

Identifiers

PMID36279695
PMCPMC9576915
OpenAlexW4306689114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.